Login Register Cart 0
Generic placeholder image

Current Indian Science

Editor-in-Chief

ISSN (Print): 2210-299X
ISSN (Online): 2210-3007

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Potential Therapeutic Role of Cannabinoid System in Alzheimer’s Disease: A Review

Author(s): Abrar Ahmad Zargar, Ranjeet Kumar*, Arvind Kumar, Ruby Gangwar and Amit Sharma

Volume 1, 2023

Published on: 13 December, 2023

Article ID: e2210299X256030 Pages: 7

DOI: 10.2174/012210299X256030231114114815

Price: $

Abstract

The purpose of the study was to investigate the role of the endocannabinoid system and the therapeutic potential benefits of cannabinoids in Alzheimer’s disease. The most frequent form of dementia in older individuals is Alzheimer's disease (AD), a progressive neurological ailment that gradually deprives people of their memory, cognitive abilities, and, ultimately, their ability to perform daily tasks. Alzheimer's disease is distinguished by a progressive deterioration in cognitive function, which includes a decline in memory, learning capacity, and thinking power. The human body's endocannabinoid system functions as a channel for cell communication. It is a neurotransmission system that is present in various regions of the body and tissues as well as assists in the control of a number of metabolic processes. Endocannabinoids, enzymes, and cannabinoid receptors all play a role in managing a variety of biological functions. In this review, we aimed to summarize the endocannabinoid system, the effect of beta-amyloid, tau-protein accumulation and neuroinflammation, potential therapeutic benefits of cannabinoids, current pre-clinical and clinical evidence for the potential therapeutic benefits, limitations, and challenges, and potential future research in the field. Emerging scientific data suggests that the ECS (Endocannabinoid system) is linked to neurodegenerative illnesses and that altering its tone may be a useful therapeutic strategy for the treatment of AD (Alzheimer’s disease).

[1]
Chiroma, S.M.; Baharuldin, M.T.H.; Taib, C.N.M.; Amom, Z.; Jagadeesan, S.; Moklas, M.A.M. Inflammation in Alzheimer’s disease: A friend or foe? Biomed. Res. Ther., 2018, 5(8), 2552-2564.
[http://dx.doi.org/10.15419/bmrat.v5i8.464]
[2]
Kumar Thakur, A.; Kamboj, P.; Goswami, K.; Ahuja, K. Pathophysiology and management of alzheimer’s disease: An overview. J. Anal. Pharm. Res., 2018, 7(2)
[http://dx.doi.org/10.15406/japlr.2018.07.00230]
[3]
Abate, G.; Uberti, D.; Tambaro, S. Potential and limits of cannabinoids in alzheimer’s disease therapy. Biology, 2021, 10(6), 542.
[http://dx.doi.org/10.3390/biology10060542] [PMID: 34204237]
[4]
Aso, E.; Ferrer, I. Cannabinoids for treatment of Alzheimer’s disease: Moving toward the clinic. Front. Pharmacol., 2014, 5, 37.
[http://dx.doi.org/10.3389/fphar.2014.00037] [PMID: 24634659]
[5]
Ruthirakuhan, M.; Herrmann, N.; Andreazza, A.C.; Verhoeff, N.P.L.G.; Gallagher, D.; Black, S.E.; Kiss, A.; Lanctôt, K.L. Agitation, oxidative stress, and cytokines in Alzheimer disease: biomarker analyses from a clinical trial with nabilone for agitation. J. Geriatr. Psychiatry Neurol., 2020, 33(4), 175-184.
[http://dx.doi.org/10.1177/0891988719874118] [PMID: 31547752]
[6]
Zhang, S.S.; Zhang, N.N.; Guo, T.T.; Sheen, L.Y.; Ho, C.T.; Bai, N.S. The impact of phyto- and endo-cannabinoids on central nervous system diseases: A review. J. Tradit. Complement. Med., 2023, 13(1), 30-38.
[http://dx.doi.org/10.1016/j.jtcme.2022.10.004] [PMID: 36685079]
[7]
Jacobs, J.A.; Sehgal, A. Anandamide metabolites protect against seizures through the TRP channel water witch in Drosophila melanogaster. Cell Rep., 2020, 31(9), 107710.
[http://dx.doi.org/10.1016/j.celrep.2020.107710] [PMID: 32492422]
[8]
Ibarra-Lecue, I.; Pilar-Cuéllar, F.; Muguruza, C.; Florensa-Zanuy, E.; Díaz, Á.; Urigüen, L.; Castro, E.; Pazos, A.; Callado, L.F. The endocannabinoid system in mental disorders: Evidence from human brain studies. Biochem. Pharmacol., 2018, 157, 97-107.
[http://dx.doi.org/10.1016/j.bcp.2018.07.009] [PMID: 30026022]
[9]
Tudorancea, I.M.; Ciorpac, M.; Stanciu, G.D.; Caratașu, C.; Săcărescu, A.; Ignat, B.; Burlui, A.; Rezuș, E.; Creangă, I.; Alexa-Stratulat, T.; Tudorancea, I.; Tamba, B.I. The therapeutic potential of the endocannabinoid system in age-related diseases. Biomedicines, 2022, 10(10), 2492.
[http://dx.doi.org/10.3390/biomedicines10102492] [PMID: 36289755]
[10]
Available from: https://www.medicalnewstoday.com/articles/endocannabinoid (Accessed on February 21, 2023).
[11]
Available from: https://svrhemp.com/what-is-the-endocannabinoid-system/ (Accessed on February 21, 2023).
[12]
Available from: https://www.kalapa-clinic.com/en/endocannabinoid-system/ (Accessed on February 21, 2023).
[13]
Lu, H.C.; Mackie, K. An introduction to the endogenous cannabinoid system. Biol. Psychiatry, 2016, 79(7), 516-525.
[http://dx.doi.org/10.1016/j.biopsych.2015.07.028] [PMID: 26698193]
[14]
Available from: https://www.healthline.com/health/endocannabinoid-system#how-it-works (Accessed on February 21 2023).
[15]
Howlett, A.C.; Barth, F.; Bonner, T.I.; Cabral, G.; Casellas, P.; Devane, W.A.; Felder, C.C.; Herkenham, M.; Mackie, K.; Martin, B.R.; Mechoulam, R.; Pertwee, R.G. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 2002, 54(2), 161-202.
[http://dx.doi.org/10.1124/pr.54.2.161] [PMID: 12037135]
[16]
Ramirez, S.H.; Haskó, J.; Skuba, A.; Fan, S.; Dykstra, H.; McCormick, R.; Reichenbach, N.; Krizbai, I.; Mahadevan, A.; Zhang, M.; Tuma, R.; Son, Y.J.; Persidsky, Y. Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J. Neurosci., 2012, 32(12), 4004-4016.
[http://dx.doi.org/10.1523/JNEUROSCI.4628-11.2012] [PMID: 22442067]
[17]
Available from: https://www.nia.nih.gov/news/sleep-loss-encourages-spread-toxic-alzheimers-protein#:~:text=It%E2%80%99s%20long%20been%20recognized%20that%20Alzheimer%E2%80%99s (Accessed on February 22 2023).
[18]
Garbuz, D.G.; Zatsepina, O.G.; Evgen’ev, M.B. [Beta Amyloid, Tau Protein, and Neuroinflammation: An Attempt to Integrate Different Hypotheses of Alzheimer’s Disease Pathogenesis]. Mol. Biol. (Mosk.), 2021, 55(5), 734-747.
[PMID: 34671002]
[19]
Heppner, F.L.; Ransohoff, R.M.; Becher, B. Immune attack: The role of inflammation in Alzheimer disease. Nat. Rev. Neurosci., 2015, 16(6), 358-372.
[http://dx.doi.org/10.1038/nrn3880] [PMID: 25991443]
[20]
Available from: https://www.nia.nih.gov/health/what-happens-brain-alzheimers-disease (Accessed on February 22 2023).
[21]
Müller, U.C.; Deller, T.; Korte, M. Not just amyloid: Physiological functions of the amyloid precursor protein family. Nat. Rev. Neurosci., 2017, 18(5), 281-298.
[http://dx.doi.org/10.1038/nrn.2017.29] [PMID: 28360418]
[22]
Haass, C.; Selkoe, D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β-peptide. Nat. Rev. Mol. Cell Biol., 2007, 8(2), 101-112.
[http://dx.doi.org/10.1038/nrm2101] [PMID: 17245412]
[23]
Kabra, A. A Systematic Review of Amyloid-β and Tau’s contribution to Neuroinflammation in Alzheimer's Disease Progression.,
[http://dx.doi.org/10.36838/v4i6.10]
[24]
BntoN JP. The role of neurofibrillary tangles in Alzheimer disease. Acta neuol. belg., 1998, 98, 165-174.
[25]
Mehta, D.; Iwamoto, K.; Ueda, J.; Bundo, M.; Adati, N.; Kojima, T.; Kato, T. Comprehensive survey of CNVs influencing gene expression in the human brain and its implications for pathophysiology. Neurosci. Res., 2014, 79, 22-33.
[http://dx.doi.org/10.1016/j.neures.2013.10.009] [PMID: 24211644]
[26]
Carmona, S.; Zahs, K.; Wu, E.; Dakin, K.; Bras, J.; Guerreiro, R. The role of TREM2 in Alzheimer’s disease and other neurodegenerative disorders. Lancet Neurol., 2018, 17(8), 721-730.
[http://dx.doi.org/10.1016/S1474-4422(18)30232-1] [PMID: 30033062]
[27]
Uddin, M.S.; Mamun, A.A.; Sumsuzzman, D.M.; Ashraf, G.M.; Perveen, A.; Bungau, S.G.; Mousa, S.A.; El-Seedi, H.R.; Bin-Jumah, M.N.; Abdel-Daim, M.M. Emerging promise of cannabinoids for the management of pain and associated neuropathological alterations in Alzheimer’s disease. Front. Pharmacol., 2020, 11, 1097.
[http://dx.doi.org/10.3389/fphar.2020.01097] [PMID: 32792944]
[28]
Ramos, Lauren Therapeutic potential of cannabinoids in the management of Alzheimer's Disease and other neurodegenerative conditions, 2019. Available from: https://core.ac.uk/download/pdf/286269001.pdf
[29]
Karl, T.; Cheng, D.; Garner, B.; Arnold, J.C. The therapeutic potential of the endocannabinoid system for Alzheimer’s disease. Expert Opin. Ther. Targets, 2012, 16(4), 407-420.
[http://dx.doi.org/10.1517/14728222.2012.671812] [PMID: 22448595]
[30]
Coles, M.; Steiner-Lim, G.Z.; Karl, T. Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer’s disease. Front. Neurosci., 2022, 16, 962922.
[http://dx.doi.org/10.3389/fnins.2022.962922] [PMID: 36117622]
[31]
Watt, G.; Karl, T. In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer’s disease. Front. Pharmacol., 2017, 8, 20.
[http://dx.doi.org/10.3389/fphar.2017.00020] [PMID: 28217094]
[32]
Sirbu, CA; Manole, AM; Vasile, TM; Toma, GS; Dobrican, LR; Vîrvara, DG; Vasiliu, O Cannabinoids–a new therapeutic strategy in neurology. Romanian J., 2022, 125(3), 349.
[http://dx.doi.org/10.55453/rjmm.2022.125.3.1]
[33]
Krishnan, S; Cairns, R; Howard, R Cannabinoids for the treatment of dementia. Cochrane Database Syst. Rev., 2009, (2), CD007204.
[http://dx.doi.org/10.1002/14651858.CD007204.pub2]
[34]
Kroon, E.; Kuhns, L.; Cousijn, J. The short-term and long-term effects of cannabis on cognition: Recent advances in the field. Curr. Opin. Psychol., 2021, 38, 49-55.
[http://dx.doi.org/10.1016/j.copsyc.2020.07.005] [PMID: 32823178]
[35]
Cooray, R.; Gupta, V.; Suphioglu, C. Current aspects of the endocannabinoid system and targeted THC and CBD phytocannabinoids as potential therapeutics for Parkinson’s and Alzheimer’s diseases: a review. Mol. Neurobiol., 2020, 57(11), 4878-4890.
[http://dx.doi.org/10.1007/s12035-020-02054-6] [PMID: 32813239]
[36]
Berry, A.J.; Zubko, O.; Reeves, S.J.; Howard, R.J. Endocannabinoid system alterations in Alzheimer’s disease: A systematic review of human studies. Brain Res., 2020, 1749, 147135.
[http://dx.doi.org/10.1016/j.brainres.2020.147135] [PMID: 32980333]
[37]
Bedse, G.; Romano, A.; Lavecchia, A.M.; Cassano, T.; Gaetani, S. The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer’s disease. J. Alzheimers Dis., 2014, 43(4), 1115-1136.
[http://dx.doi.org/10.3233/JAD-141635] [PMID: 25147120]
[38]
Aso, E.; Juvés, S.; Maldonado, R.; Ferrer, I. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. J. Alzheimers Dis., 2013, 35(4), 847-858.
[http://dx.doi.org/10.3233/JAD-130137] [PMID: 23515018]
[39]
Available from: https://en.wikipedia.org/wiki/Cannabinol (Accessed on 21 July 2023).
[40]
Available from: https://en.wikipedia.org/wiki/Tetrahydrocannabinol (Accessed on 21 July 2023).

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy